



Updated Monthly

December 7, 2023

Prepared for:



THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:





## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

  @G2Gconsulting





# GBG Report

Updated Monthly

December 7, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

## TABLE OF CONTENTS

### New Opportunities

Aging.....	2
Amyotrophic Lateral Sclerosis .....	2
Bioengineering.....	3
Biomedical Research.....	3
Biotechnology and Biomanufacturing.....	3
Cancer .....	3
Cardiovascular and Pulmonary Health.....	5
Central Nervous System .....	5
Cognitive and Brain Health.....	6
Communication Disorders.....	7
Coronavirus .....	7
Diagnostics .....	8
Down Syndrome .....	8
Endocrine and Metabolic Diseases .....	8
Epilepsy.....	8
Genomics .....	9
Health IT & Data.....	9
HIV/AIDS .....	10
Immunology & Infectious Disease .....	10
Mental Health.....	11
Patient-Centered Research .....	11

Rare Diseases .....	12
Small Business Development .....	12
Substance Use Disorder .....	13
Telemedicine .....	15
Therapeutics.....	15
Toxic Exposures .....	17
Veterinary Medicine.....	17
Vision Health .....	18

### Recurring Opportunities

Advanced Research Projects Agency for Health .....	19
Air Force .....	19
Army.....	20
BARDA .....	21
DARPA .....	22
Defense Threat Reduction Agency .....	22
Department of Energy.....	23
National Science Foundation .....	23
Navy .....	23

<b>GBG Acronyms .....</b>	<b>24</b>
---------------------------	-----------



**December 15, 2023** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE to all) and 10:30-11:00am EST (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

**Conference alert:** G2G will be attending the [42<sup>nd</sup> annual JP Morgan Healthcare Conference](#) from January 8-11 in San Francisco, and participating in a special panel event on *Equity in Health: Perspectives on Women’s Health Innovation* on January 9. Please reach out if you’re attending the conference and would like to connect.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AGING (1)</b>		
1.	Resources to Promote Coordination and Collaboration across Deeply Phenotyped Longitudinal Behavioral and Social Studies of Aging (U24 Clinical Trial Not Allowed) (NIH/NIA)  RFA-AG-25-006	This NOFO invites applications that propose to establish a Resource Development Network (RDN). The aim of the RDN will be to create infrastructure needed to promote and support coordination, collaboration, and innovation across deeply phenotyped longitudinal behavioral and social studies of aging. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-006.html</a>	Up to \$1.6 million per year, for up to 5 years	Letter of intent: 1/14/24 Proposal: 2/14/24
		<b>AMYOTROPHIC LATERAL SCLEROSIS (1)</b>		
2.	Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NIH)  RFA-NS-24-029	This NOFO encourages grant applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-029.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-029.html</a>	Dependent upon proposal, for up to 4 years	Letter of intent: 1/22/24 Proposal: 2/22/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BIOENGINEERING (1)</b>		
3.	Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44/UT1/UT2 - Clinical Trial Not Allowed) (NIH/NCATS)  RFA-TR-23-017 (U43/U44) RFA-TR-23-018 (UT1/UT2)	These NOFOs seek to fund technology development research efforts in instrumentation innovation and approaches for automation and miniaturization of MPS. The technology development proposed should have the potential to significantly propel the field of MPS forward and have the potential to have a large impact on the future analysis of safety and efficacy assessment of therapeutics. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-017.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-017.html</a> (U43/U44) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html</a> (UT1/UT2)	Up to \$350,000, for up to 6 months (Phase I) Up to \$2.15 million, for up to 2 years (Phase II)	Letter of intent: 1/22/24 Proposal: 2/22/24
		<b>BIOMEDICAL RESEARCH (1)</b>		
4.	Complement-Animal Research in Experimentation (Complement-ARIE) Challenge (NIH)  NOT-RM-23-025	The Complement-ARIE Challenge seeks to propel the development and refinement of human-centric New Approach Methodologies (NAMs), by developing approaches that complement or replace animal models. Solutions must include next-generation innovation in NAMs for complex in vitro human-derived cell- or tissue-based models, in silico multi-scale systems, in chemico approaches to emulate human biology, and/or integrated NAMs with associated Findable, Accessible, Interoperable, and Reusable (FAIR) datasets and AI-engines. Solutions must demonstrate substantial advancement from the current state-of-the art models and technologies. <a href="https://www.challenge.gov/?challenge=complement-arie">https://www.challenge.gov/?challenge=complement-arie</a>	Up to \$50,000	Proposal: 1/11/24
		<b>BIOTECHNOLOGY AND BIOMANUFACTURING (1)</b>		
5.	Accelerating Biomanufacturing Innovation: Advancing Solutions for Greener Chemistry, Low-Resource Environments, and Process Intensification (BioMADE)	Project Call 4.0 will follow a unique format, focusing on a set of cross-disciplinary solutions that advances biomanufacturing innovation. The focus areas are: Accelerate the transition to greener chemistry; Develop biomanufacturing solutions for low-resource environments; Process integration and process intensification. Projects must also align to a minimum of one BioMADE program area: Technology and Innovation, Education and Workforce Development, and/or Safety, Security, Sustainability, and Social Responsibility (4S). <a href="https://www.biomade.org/news/project-call-4">https://www.biomade.org/news/project-call-4</a>	Dependent upon proposal 1:1 cost share required	White paper: 12/20/23
		<b>CANCER (14)</b>		
6.	Pre-Announcement: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 CT Required) (NIH/NCI)  NOT-CA-24-010	The overall goal of the NOFO is to advance new cell therapy strategies into clinical testing for the treatment of solid tumors in pediatric cancer patients. The successful applications will add to -the newly established Cancer Adoptive Cellular Therapy (Can-ACT) Network, dedicated to developing innovative cell therapy approaches for the treatment of solid tumors in pediatric and adult tumors. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-010.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-010.html</a>	Up to \$3 million	Estimated post date: 1/3/24 Estimated proposal date: 3/6/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
7.	Pre-Announcement: NCI's Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (U54 Clinical Trial Optional) (NIH/NCI)  NOT-CA-24-008	This NOFO supports a collaborative network of SPOREs, under the U54 cooperative agreement mechanism, that is uniquely focused on CHD-MH translational research in populations who are underserved. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-008.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-008.html</a>	Up to \$1.6 million per year	Estimated post date: 2/23/24 Estimated proposal date: 9/25/24
8.	Basic and Clinical Cancer Research: Molecular and Cellular Analysis Technologies and Biospecimen Science Technologies (R61/R33 Clinical Trial Not Allowed) (NIH/NCI)  RFA-CA-24-008 (R61) RFA-CA-24-009 (R33) RFA-CA-24-010 (R61) RFA-CA-24-011 (R33)	These NOFOs solicit applications proposing exploratory research projects focused on highly innovative technologies, both novel and those requiring further development, for basic and clinical cancer research. Highly innovative technologies are sought that offer capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology; and for maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html</a> (R61) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-009.html</a> (R33) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html</a> (R61) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html</a> (R33)	Up to \$150,000 per year, for up to 3 years (R61) Up to \$300,000 per year, for up to 3 years (R33)	Letter of intent: 3/1/24 Proposal: 4/1/24
9.	Pre-Announcement: FY24 Breast Cancer Research Program (BCRP) (DoD/CDMRP)	Five awards are anticipated: Breakthrough Award (includes 4 funding levels and partnering options); Era of Hope Scholar Award; Clinical Research Extension Award; Transformative Breast Cancer Consortium Award; and Transformative Breast Cancer Consortium Development Award. Applications submitted to the FY24 BCRP must address one or more of the <a href="#">overarching challenges</a> . <a href="https://cdmrp.health.mil/pubs/press/2024/24bcrrpreann">https://cdmrp.health.mil/pubs/press/2024/24bcrrpreann</a>	Up to \$25 million, for up to 4 years Dependent upon award mechanism	TBD
10.	NOSI: Exploratory Cancer Immunology Projects and Technologies (ExcITe) (NIH/NCI)  NOT-CA-24-016	The NCI encourages applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. Research projects should focus on fundamental areas of cancer immunology, including innate and adaptive immune responses, tumor-immune ecosystems and their dynamic interactions, the immune response to metastases, systemic immune networks, immunosurveillance, tumor immune evasion, or immunomodulation. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-016.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-016.html</a>	Up to \$275,000, for up to 2 years	Multiple deadlines; NOSI open through 11/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
11.	Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) (NIH/NCI)  RFA-CA-24-021	The overall goal of the NOFO is to advance new cell therapy strategies into clinical testing for the treatment of solid tumors in pediatric cancer patients. The successful applications will add to -the newly established Cancer Adoptive Cellular Therapy (Can-ACT) Network, dedicated to developing innovative cell therapy approaches for the treatment of solid tumors in pediatric and adult tumors.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-021.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-021.html</a>	Up to \$900,000 per year, for up to 2 years (UG3) Up to \$1.5 million per year, for up to 3 years (UH3)	Letter of intent: 2/6/24 Proposal: 3/6/24
		<b>CARDIOVASCULAR AND PULMONARY HEALTH (2)</b>		
12.	NHLBI Program Project Applications (Po1 Clinical Trials Optional) (NIH/NHLBI)  PAR-24-065	This NOFO invites submission of investigator-initiated programs; applications may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application must include at least three related research projects that share a common central theme, focus, and/or overall objective.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-065.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-065.html</a>	Dependent upon proposal and number of projects, for up to 5 years	Letter of intent: 3/25/24 Proposal: 5/25/24
13.	Cardiovascular Repository – Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed). (NIH/NIDDK/NHLBI)  RFA-DK-23-021	CaRe-T1D will be the source of well-characterized and preserved human cardiovascular tissue for the consortium. This resource will enable ground-breaking research on human tissue from donors with T1D, T2D, and without diabetes. CaRe-T1D will also serve as the CC and bioinformatics core of the consortium. The goal of this NOFO is to attract investigative teams with complementary interests and expertise who will make full use of these resources through individual and collaborative studies to advance the knowledge of the pathogenesis of CVD in T1D.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-021.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-021.html</a>	Up to \$600,000 per year, for up to 3 years	Letter of intent: 3/11/24 Proposal: 4/11/24
		<b>CENTRAL NERVOUS SYSTEM (1)</b>		
14.	Pre-Announcement: BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18 - Clinical Trial Not Allowed) (NIH)  NOT-NS-24-017	This NOFO will solicit applications that would support development and preclinical testing, beginning with proof of concept, of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-017.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-017.html</a>	Up to \$750,000 per year	Estimated post date: 1/1/24 Estimated proposal date: 5/25/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COGNITIVE AND BRAIN HEALTH (11)</b>		
15.	NOSI: Telehealth for People and Families Living with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (NIH/NIA)  NOT-AG-23-060	This NOSI indicates NIA's interest in (1) retrospective and new examinations that determine the impact of telehealth on cost, access, quality, timeliness, and equity of care for people and families living with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), and (2) prospectively identify telehealth care delivery methods that work well for people and families living with AD/ADRD. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-060.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-060.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/12/24
16.	BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Optional) (NIH)  RFA-DA-24-042	This NOFO seeks applications proposing a set of planning activities that will lay the groundwork for a scientific project aimed at integrating complementary theories and methods to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the level of the organism, with synchronous capture of changes in the organism's social or physical environment; and 2) develop data science and computational methods that allow for integration of multidimensional behavioral and environmental data representing multiple timescales, and that will establish of a conceptual and/or computational model of behavior as a complex dynamic system. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-042.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-042.html</a>	Up to \$450,000, for up to 2 years	Letter of intent: 1/15/24 Proposal: 2/15/24
17.	NINDS Exploratory Clinical Trials for Small Business (R41/R42/R43/R44 CT Required) (NIH/NINDS)  PAR-24-044 (R41/R42) PAR-23-311 (R43/R44)	These NOFOs provide a vehicle for SBIR grant applications for investigator-initiated exploratory clinical trials to NINDS. The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-044.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-044.html</a> (R41/R42) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html</a> (R43/R44)	Up to \$295,924 per year (Phase I) Up to \$1,972,828 per year, for up to 2 years (Phase II) <a href="#">Waiver topics</a> may exceed these amounts	Letter of intent: 3/5/24 Proposal: 4/5/24
18.	Pre-Announcement: Open Measurement Coordinating Network for Non-Pharmacological AD/ADRD Primary Prevention Trials (U24 CT Not Allowed) (NIH/NIA)  NOT-AG-23-061	This NOFO will solicit applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological AD/ADRD Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-061.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-061.html</a>	Up to \$5 million per year	Estimated post date: 2/1/24 Estimated proposal date: 6/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COMMUNICATION DISORDERS (2)</b>		
19.	In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional/U01 Clinical Trial Required) (NIH/NIDCD)  RFA-DC-24-004 (R01) RFA-DC-24-005 (U01)	These NOFOs aim to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear, and high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-24-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-24-004.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-24-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-24-005.html</a> (U01)	Up to \$500,000 per year, for up to 5 years	Letter of intent: 1/1/24 Proposal: 2/1/24
		<b>CORONAVIRUS (6)</b>		
20.	NOSI: Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21) (NIH)  NOT-OD-24-026	The research objective of this NOSI is to stimulate data science approaches by catalyzing the scientific value and revealing scientific insights through secondary analysis of existing data collected from the RADx programs. The research topic areas may include, but are not limited to, biomedical, clinical, social, ethical, and behavioral issues. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-026.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-026.html</a>	Up to \$275,000, for up to 2 years (R21)	Multiple deadlines; NOSI open through 7/15/24
21.	NextGen Vaccinations: Phase 2B Clinical Trial Execution (HHS/BARDA)  RPP-24-04-NGVx	BARDA is requesting project proposals for the advanced clinical development and assessment of next-generation vaccines and therapeutics for COVID-19. BARDA has identified a capability gap for COVID-19 vaccines that, when compared to current vaccines, offer improved durability, breadth of protection, and/or transmission blocking in the face of new SARS-CoV-2 variants. <a href="https://www.rpv.org/solicitation/24-04-ngvx/">https://www.rpv.org/solicitation/24-04-ngvx/</a>	Dependent upon proposal and award mechanism	Proposal: 1/5/24
22.	Enabling Technology – Decentralized Clinical Trial – Home Focus (HHS/BARDA)  RPP-24-02-HomeFocus	As the COVID-19 pandemic evolves, characterization of correlates of protection (CoPs) are critical for ongoing vaccine development and optimization as variants and subvariants continue to emerge. As part of Project NextGen, BARDA intends to leverage immunogenicity data from multiple clinical trials of investigational next-generation COVID-19 vaccines and FDA licensed or authorized COVID-19 vaccines to inform a broader understanding of immunologic correlates of vaccine protection. BARDA is requesting project proposals to conduct a study designed to assess potential CoP using humoral immunogenicity data correlated to symptomatic COVID-19 following vaccination with an FDA licensed/authorized COVID-19 vaccine. <a href="https://www.rpv.org/solicitation/24-02-homefocus/">https://www.rpv.org/solicitation/24-02-homefocus/</a>	Dependent upon proposal and award mechanism	Proposal: 1/10/24





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CORONAVIRUS</b>		
23.	COVID-19 Monoclonal Antibody Therapeutics for PrEP (HHS/BARDA)  RPP-24-03-PrEP	BARDA has previously identified a capability gap for therapeutics that provide protection through Pre-exposure Prophylaxis (PrEP) and treatment against new SARS-CoV-2 variants. The purpose of this project is to partner with developers and other organizations to advance the clinical development of Next-Generation Therapeutics for COVID-19. The goal of this project is to provide better COVID-19 solutions and bolster preparedness and response against future health security threats.  <a href="https://www.rpv.org/solicitation/24-03-prep/">https://www.rpv.org/solicitation/24-03-prep/</a>	Dependent upon proposal and award mechanism	Proposal: 1/19/24
		<b>DIAGNOSTICS (1)</b>		
24.	ITAP for Diagnostic Mpox Lesion Panel (POCTRN)	NIBIB is soliciting proposals to address the diagnostic needs for point-of-care (POC) lesion panel tests. This includes tests intended for the direct detection and differentiation of mpox virus (MPXV), herpes simplex virus types 1 and 2 (HSV1/2), Treponema pallidum (Syphilis), and varicella-zoster virus (VZV) in lesion swab specimens (“lesion panel”).  <a href="https://www.poctrn.org/itap-diagnostic-mpox-lesion-panel">https://www.poctrn.org/itap-diagnostic-mpox-lesion-panel</a>	Dependent upon contract	Proposal: 1/22/24
		<b>DOWN SYNDROME (1)</b>		
25.	Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed) (NIH)  PAR-24-081	This NOFO invites applications to submit samples to NIH INCLUDE Project (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE)-supported resources to generate a large volume of integrated genomic and multi-omics data that will facilitate discovery of the molecular mechanisms of health conditions related to Down syndrome.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-081.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-081.html</a>	N/A	Letter of intent: 2/13/24 Proposal: 3/13/24
		<b>ENDOCRINE AND METABOLIC DISEASES (1)</b>		
26.	Epidemiologic Cohort Study of Interstitial Cystitis (CDC/ERA)  RFA-DP-24-031	The purpose of this NOFO is to follow a cohort of interstitial cystitis (IC) patients over time, define the demographic and clinical patterns of IC, and document its impact on the health of affected people.  <a href="https://www.grants.gov/search-results-detail/348751">https://www.grants.gov/search-results-detail/348751</a>	Up to \$900,000 per year, for up to 5 years	Letter of intent: 1/10/24 Proposal: 2/10/24
		<b>EPILEPSY (4)</b>		
27.	Pre-Announcement: FY24 Epilepsy Research Program (ERP) (DoD/CDMRP)	Four awards are anticipated: Idea Development Award, Leveraging Research Award; Research Partnership Award; Virtual Post-Traumatic Epilepsy Research Faculty Award. Applications should address one or more of the Focus Areas: Markers and Mechanisms; Epidemiology; Longitudinal Studies; Innovative Research.  <a href="https://cdmrp.health.mil/pubs/press/2024/24erppreann">https://cdmrp.health.mil/pubs/press/2024/24erppreann</a>	Up to \$1.2 million, for up to 3 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>GENOMICS (1)</b>		
28.	Targeted Genome Editor Delivery (TARGETED) Challenge (NIH)	The TARGETED Challenge aims to improve the current state of in vivo delivery technologies for genome editors in two Target Areas: 1) programmable delivery systems to deliver genome editing machinery that can target specific tissues or cell types, and 2) highly efficient non-viral delivery systems capable of crossing the blood brain barrier (BBB) to deliver genome editing machinery to a substantial proportion of clinically relevant cell types in the central nervous system (CNS). <a href="https://www.challenge.gov/?challenge=targeted-challenge">https://www.challenge.gov/?challenge=targeted-challenge</a>	Up to \$1 million	Phase 2 Proposal: 12/13/23
		<b>HEALTH IT &amp; DATA (3)</b>		
29.	Pre-Announcement: Secure Data Sharing Tool to Support Deduplication of Cases in the National HIV Surveillance System (CDC/NCHHSTP)  CDC-RFA-PS-24-0121	This NOFO will support a more efficient method for jurisdictions to de-duplicate cases reported to the National HIV Surveillance System. The recipient will develop and provide access to a privacy data-sharing tool that identifies potential duplicates across 59 jurisdictions; allow for secure, encrypted submission and matching of person-level HIV surveillance data; ensure data security, confidentiality, and privacy per CDC standards; recruit and negotiate with the 59 jurisdictions to participate; and provide them a report on matching levels. <a href="https://www.grants.gov/search-results-detail/351008">https://www.grants.gov/search-results-detail/351008</a>	Up to \$400,000	Estimated post date: 1/26/24 Estimated proposal date: 5/1/24
30.	Pre-Announcement: Agile Medical Countermeasure Decision Support Tool (AMDST) Prototype (MTEC)  MTEC-24-04-AMDST	This RPP is focused on the development of a software prototype that will allow a medical planner to assess the residual operational risk for a mission after layering in threat risk, medical countermeasure (MCM) risk-benefit tradeoffs, and fielding risk during mission planning. The AMDST layering model is intended to include all MCMs for a potential threat, including FDA-approved, repurposed, and investigational drugs. <a href="https://mtec-sc.org/wp-content/uploads/2023/11/MTEC-24-04-AMDST-Pre-Announcement.pdf">https://mtec-sc.org/wp-content/uploads/2023/11/MTEC-24-04-AMDST-Pre-Announcement.pdf</a>	Dependent upon proposal, for up to 3 years	TBD
31.	Safeguarding Warfighter Medical Data: Secure Encrypted Transmission of Physiologic Monitoring (PhysMon) Data (DoD/Navy)  N241-Do2	The candidate technology will demonstrate the ability to securely transmit medical endpoint data from an existing wearable PhysMon device. The technology developed will eventually be required to be adapted to a flight environment on military aircraft with special emphasis on naval environments featuring moisture and salt. Highly desirable criteria include minimal size profile, low power requirements, long battery life, minimum weight and bulk, wireless, and no interference with flight/safety gear. <a href="https://www.dodsbirsttr.mil/topics-app/">https://www.dodsbirsttr.mil/topics-app/</a>	Up to \$1.3 million, for up to 3.5 years	Proposal: 2/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HIV/AIDS (3)</b>		
32.	Humoral Immunology Core Laboratory for AIDS Vaccine Research (NIH)  75N93023R00012	The purpose of the contract will be to conduct, develop, acquire, improve, and implement assays to evaluate and characterize the humoral immune responses of nonhuman primates (NHP) that have been immunized with candidate HIV or SIV vaccines or infected with SIV, SHIV, or HIV, with a focus on studies conducted by the NIAID Simian Vaccine Evaluation Units (SVEUs) and by investigators supported by, or collaborating with, NIH. <a href="https://sam.gov/opp/0153doeff31b409d8d2047cdf4b7875d/view">https://sam.gov/opp/0153doeff31b409d8d2047cdf4b7875d/view</a>	Dependent upon contract	Proposal: 2/16/24
33.	Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-25-009 (R01) RFA-DA-25-010 (R21)	These NOFOs support studies to expand our knowledge of mechanisms driving autophagy and to identify autophagy pathways that can be exploited to control HIV infection and pathogenesis of comorbidities in the context of addictive substance use. They invite mechanistic studies and preclinical studies testing effects of compounds known to interfere with autophagy pathways on HIV infection and immune system. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-009.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-010.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 10/14/24 Proposal: 11/14/24
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (3)</b>		
34.	NOSI: Development of Organotypic Culture Models for Transplantation Immunology Research (NIH/NIAID)  NOT-AI-23-064	This NOSI encourages applications that focus on the development and validation of tissue-, stem-, or progenitor-cell-derived “3D” organotypic culture models (OCM) for transplantation immunology research. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-064.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-064.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/16/26
35.	Antigens Predicted for Broad Viral Efficacy through Computational Experimentation (APECx) (ARPA-H)  75N99224R00001	The APECx program aims to create a toolkit to enable accurate chimeric and broadly efficacious vaccine Ag discovery through predictive modeling, high-throughput functional experimentation, and protein engineering. To fundamentally transform the vaccine research and development (R&D) sector, APECx will develop an innovative viral Ag prediction pipeline for broad efficacy by combining expedited experimental protein structure and function determination with highthroughput Ag screening. <a href="https://sam.gov/opp/6254723d96854573a6643803eefcf3c1/view">https://sam.gov/opp/6254723d96854573a6643803eefcf3c1/view</a>	Dependent upon proposal and award mechanism	Abstract: 12/15/23 Invitation only proposal: 2/16/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MENTAL HEALTH (10)</b>		
36.	<p>Early Psychosis Intervention Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional) and Data Coordinating Center (U24 CT Not Allowed) (NIH/NIMH)</p> <p>RFA-MH-24-105 (P01) RFA-MH-24-106 (U24)</p>	<p>These NOFOs solicit applications from scientific hubs to support learning health care research in clinics offering evidence-based Coordinated Specialty Care (CSC) to persons in the early stages of psychotic illness. Each scientific hub will link multiple early psychosis service programs through (1) the EPINET Core Assessment Battery (CAB) of early psychosis clinical features, CSC services, and treatment outcomes; (2) informatics tools to collect de-identified, person-level data across sites; and (3) a unified approach for analyzing pooled data and disseminating promising findings rapidly across the network.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-105.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-105.html</a> (P01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-106.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-106.html</a> (U24)</p>	Up to \$1 million per year, for up to 5 years	Letter of intent: 2/29/24 Proposal: 3/29/24
37.	<p>NOSI: SBIR/STTR Program Priorities to Bridge Gaps in Advancing the NIMH Mission (NIH/NIMH)</p> <p>NOT-MH-24-110</p>	<p>Applications linked to this NOSI are expected to represent significant advances and innovation. Specific areas of research interest include: Neurotechnology development to enhance research on brain structure and function; Drug Discovery/Development; Novel Brain Modulation Methods/Devices as Potential Therapeutics; Biological Markers for CNS Dysregulation/Function and Mental Illness; Digital Health Technologies; and Technologies Addressing Basic, Behavioral and Implementation Science related to people living with HIV.</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-110.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-110.html</a></p>	Up to \$450,000 per year, for up to 2 years (Phase I) Up to \$750,000 per year, for up to 3 years (Phase II)	Multiple deadlines; NOSI open through 1/6/27
38.	<p>NOSI: SBIR/STTR High-Priority Areas for Digital Mental Health Innovations (NIH/NIMH)</p> <p>NOT-MH-24-120</p>	<p>Rigorous research is needed to test the efficacy, effectiveness, or implementation of innovative digital mental health interventions or service delivery tools. Novel technologies are also needed to understand the trajectory and etiology of mental disorders, to predict and prevent mental illness, and to support basic or clinical mental health research and clinical trial design/implementation. Responsive areas of research include: Assessment; Intervention Refinement and Testing; and Service Interventions and Service Delivery.</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-120.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-120.html</a></p>	Up to \$450,000 per year, for up to 2 years (Phase I) Up to \$750,000 per year, for up to 3 years (Phase II)	Multiple deadlines; NOSI open through 1/6/27
		<b>PATIENT-CENTERED RESEARCH (3)</b>		
39.	<p>Pre-Announcement: Engagement Award: Stakeholder Convening Support -- April 2024 Cycle (PCORI)</p>	<p>This FOA provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations.</p> <p><a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-april-2024-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-april-2024-cycle</a></p>	Up to \$125,000, for up to 1 year	System opens: 1/16/24 Letter of intent: 4/4/24 Invited proposals: 7/10/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>PATIENT-CENTERED RESEARCH</b>		
40.	Pre-Announcement: Engagement Award: Dissemination Initiative -- April 2024 Cycle (PCORI)	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. <a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-april-2024-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-april-2024-cycle</a>	Up to \$300,000, for up to 2 years	System opens: 1/16/24 Letter of intent: 4/4/24 Invited proposals: 7/10/24
41.	Pre-Announcement: Engagement Award: Capacity Building -- April 2024 Cycle (PCORI)	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. <a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-april-2024-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-april-2024-cycle</a>	Up to \$300,000, for up to 2 years	System opens: 1/16/24 Letter of intent: 4/4/24 Invited proposals: 7/10/24
		<b>RARE DISEASES (1)</b>		
42.	Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required) (NIH/NCATS)  RFA-TR-24-001	The purpose of this NOFO is to provide support for basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease, and in the process to identify and overcome challenges in adapting the oncology basket trial model to rare diseases. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-001.html</a>	Up to \$306,872 for up to 6 months (Phase I) Up to \$2,045,816, for up to 2 years (Phase II) <a href="#">Waiver topics</a> may exceed these amounts.	Letter of intent: 2/14/24 Proposal: 3/15/24
		<b>SMALL BUSINESS DEVELOPMENT (1)</b>		
43.	Defense Health Agency SBIR 24.1 - Phase I & Direct to Phase II (DoD/DHA)  DHA SBIR 24.1	Topics include: Psoralen-UV-A Irradiation Based High-throughput Pathogen Inactivation Device; Development of a Junctional Tourniquet; Rapid Manufacturing of Personalized Braces and Splints for Musculoskeletal Injury; and Wireless, Wearable Personal Metabolic Sensor. <a href="https://www.dodsbirsttr.mil/topics-app/">https://www.dodsbirsttr.mil/topics-app/</a>	Up to \$250,000, for 6 months (Phase I) Up to \$1.3 million, for up to 2 years (Phase II)	Proposal: 2/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SUBSTANCE USE DISORDER (21)</b>		
44.	The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required) (NIH/NIDA)  RFA-DA-25-027	Applicants should demonstrate their capacity to conduct large multi-site clinical trials and briefly describe a research agenda likely to have substantial public health significance and impact on clinical practice. The proposed infrastructure and research agenda should illustrate how the proposed Node could participate in the research network to improve SUD treatment and advance research in the field.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-027.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-027.html</a>	Up to \$500,000 per year, for up to 7 years	Letter of intent: 2/13/24 Proposal: 3/13/24
45.	National Drug Early Warning System Coordinating Center (U01 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-25-029	This initiative aims to assess the current availability of data relevant to the understanding and early detection of drug use patterns and trends in communities across the United States; identify, compile, analyze, and triangulate data and resources from multiple sources to identify and contextualize emerging drug threats; and disseminate findings, data, and resources to key audiences in communities who can use the data to inform their response.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-029.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-029.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 2/20/24 Proposal: 3/20/24
46.	Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional) (NIH/NIDA/NIAAA)  PAR-24-062	This NOFO encourages research that facilitates rapid translation from one discipline to another; supports community/stakeholder engagement in substance use treatment and prevention clinical trials; or reduces the research to practice gap through the rapid transition from pilot study to clinical trial, or effectiveness to implementation study.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-062.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-062.html</a>	Up to \$350,000 for up to 2 years (R61) Up to \$750,000 per year, for up to 4 years (R33)	Letter of intent: 1/14/24 Proposal: 2/14/24
47.	Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed/R34 - Clinical Trial Optional) (NIH/NIDA/NIAAA)  RFA-DA-25-030 (R21) RFA-DA-25-031 (R34)	These NOFOs encourage exploratory and developmental research to better understand adolescent illicit fentanyl use and overdose patterns among adolescents at high risk for overdose; and pilot work and preliminary research to support preparation for large-scale, rigorous trials that will guide the expansion of effective, non-stigmatizing overdose prevention, substance use disorder (SUD) treatment, and recovery services for adolescents.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-030.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-030.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-031.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-031.html</a> (R34)	Up to \$275,000, for up to 2 years (R21) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 2/13/24 Proposal: 3/13/24
48.	Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) (NIH/NIDA)  PAR-24-064	The primary objective of this NOFO is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-064.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-064.html</a>	Up to \$500,000 per year, for up to 2 years (UG3) Dependent upon proposal, for up to 3 years (UH3)	Letter of intent: 2/26/24 Proposal: 3/26/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SUBSTANCE USE DISORDER</b>		
49.	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34/R61/R33 Clinical Trial Optional) (NIH/NIAAA)  PAR-24-067 (R34) PAR-24-068 (R61/R33)	These NOFOs focus on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-067.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-067.html</a> (R34) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-068.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-068.html</a> (R61/R33)	Up to \$450,000, for up to 3 years (R34) Up to \$350,000, for up to 2 years (R61) Up to \$500,000 per year, for up to 3 years (R33)	Letter of intent: 1/16/24 Proposal: 2/16/24
50.	NOSI: Development and Application of Novel Chemical Approaches to Discover Therapeutic Targets for Substance Use Disorders (NIH/NIDA)  NOT-DA-25-027	This NOSI aims to encourage research on the development and application of novel chemical approaches and tools to gain a better understanding of the biological processes, targets, and pathways that could be exploited for the development of therapeutics for the treatment of substance use disorders (SUDs). <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-25-027.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-25-027.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/7/27
51.	Alcohol Research-Related Resource Award (R24 Clinical Trial Not Allowed) (NIH/NIAAA)  PAR-24-071	This NOFO encourages investigator-initiated applications that may be critical to enhancing synergies among all programs that address the specific mission of NIAAA. This grant mechanism supports investigator-initiated resources designed to provide materials and services to support and advance biomedical, behavioral, and social health research on a national basis. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-071.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-071.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 12/26/23 Proposal: 1/25/24
52.	Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-25-023	This NOFO aims to support research programs that adopt innovative scalable technologies to inventory, register and molecularly profile distributed cell ensembles encoding the effects of addictive substances, across various stages of exposure. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-023.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-023.html</a>	Up to \$700,000 per year, for up to 5 years	Letter of intent: 1/20/24 Proposal: 2/21/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>TELEMEDICINE (1)</b>		
53.	Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) (NIH)  PAR-23-318	This NOFO encourages exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for LMICs that utilize new or emerging technology, platforms, systems, and/or analytics.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-318.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-318.html</a>	Up to \$125,000 per year, for up to 2 years (R21) Up to \$200,000 per year, for up to 3 years (R33)	Letter of intent: 2/22/24 Proposal: 2/22/24
		<b>THERAPEUTICS (9)</b>		
54.	Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required) (FDA/CDER)  RFA-FD-24-008	This NOFO supports the research and development necessary to advance non-invasive technologies to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-008.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-008.html</a>	Up to \$250,000 for the first year, up to \$500,000 per year for the second 2 years, up to \$250,000 for the fourth and final year	Letter of intent: 2/15/24 Proposal: 3/31/24
55.	Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional (FDA/CDER)  RFA-FD-24-009	The purpose of this NOFO is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-009.html</a>	Up to \$250,000 per year, for up to 3 years	Letter of intent: 2/15/24 Proposal: 3/31/24
56.	Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional (FDA/CDER)  RFA-FD-24-006	The objective of this NOFO is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-006.html</a>	Up to \$300,000 for the first year, up to \$250,000 per year for the remaining 2 years	Letter of intent: 2/15/24 Proposal: 3/31/24





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>THERAPEUTICS</b>		
57.	Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed (FDA/CDER)  RFA-FD-24-005	Computational fluid dynamics (CFD) has played a crucial role in providing an alternative bioequivalence (BE) approach for generic orally inhaled drug products (OIDPs), in addition to comparative clinical endpoint or pharmacodynamic BE studies, as a relatively cost- and time-efficient complement to benchtop and clinical experiments that has been widely used in developing and assessing generic inhaler devices. ML has been gaining more attention as a potential tool to alleviate limitations that arise in CFD. The purpose of this grant is to develop a methodology to integrate ML with CFD models of OIDPs to promote alternative BE studies to enhance and accelerate the development and approval of generic OIDPs. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-005.html</a>	Up to \$300,000 per year, for up to 2 years	Letter of intent: 2/15/24 Proposal: 3/31/24
58.	Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed (FDA/CDER)  RFA-FD-24-011	The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereochemically controlled synthesis and biological activity assessment using in vitro and animal models. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-011.html</a>	Up to \$300,000 for the first year Up to \$500,000, for the second year Up to \$400,000 for the third year	Letter of intent: 2/15/24 Proposal: 3/31/24
59.	Identification of Drug-related and Formulation-Related Factors that Result in Alcohol Dose Dumping of Modified Release Oral Drug Products (U01) Clinical Trial Not Allowed (FDA/CDER)  RFA-FD-24-010	The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-010.html</a>	Up to \$250,000 for the first year Up to \$200,000 for the second year	Letter of intent: 2/15/24 Proposal: 3/31/24
60.	Pre-Announcement: Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01) (FDA)  FOR-FD-24-008	The proposed work directly supports the U.S. FDA's stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. <a href="https://www.grants.gov/search-results-detail/351131">https://www.grants.gov/search-results-detail/351131</a>	Up to \$350,000	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>THERAPEUTICS</b>		
61.	Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed (FDA/CDER)  RFA-FD-24-007	The objective of this funding opportunity is to explore the use of RWD to compare clinical outcomes in patients who switch between a complex generic drug product(s) and the reference listed drug(s). The goal of this research is to develop an RWD algorithmic model to support generic product post-market surveillance that supplements the current reporting approach, facilitates timely and definitive regulatory action, and is able to be implemented in an automated and repeatable fashion. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-007.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-007.html</a>	Up to \$300,000 for the first year, up to \$500,000 per year for the remaining 2 years	Letter of intent: 2/15/24 Proposal: 3/31/24
62.	Pre-Announcement: Collaborations to Enhance Drug Development and Regulatory Science (FDA)  FOR-FD-24-014	FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. <a href="https://www.grants.gov/search-results-detail/351254">https://www.grants.gov/search-results-detail/351254</a>	Up to \$5 million	TBD
		<b>TOXIC EXPOSURES (1)</b>		
63.	Lead Detect Prize (CDC)	The Lead Detect Prize seeks to accelerate the development of next-generation point-of-care blood lead testing technology. The first phase of the multiphase challenge calls upon researchers and innovators across disciplines to submit concepts and development plans for advanced point-of-care blood lead tests that could detect very low blood lead levels with reduced risk of blood sample contamination from the environment. <a href="https://www.challenge.gov/?challenge=lead-detect-prize">https://www.challenge.gov/?challenge=lead-detect-prize</a>	Total cash prizes of \$1 million for Phase 1 and Phase 2	Proposal: 1/22/24
		<b>VETERINARY MEDICINE (1)</b>		
64.	Pre-Announcement: Minor Use Minor Species Development of Drugs (R01) (FDA/CVM)  FOR-FD-24-013	This NOFO will solicit R01 grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). <a href="https://www.grants.gov/search-results-detail/351252">https://www.grants.gov/search-results-detail/351252</a>	Up to \$250,000	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>VISION HEALTH (1)</b>		
65.	NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required) (NIH/NEI)  PAR-24-066	This NOFO supports applications for clinical trials to investigate the safety and/or efficacy of screening, diagnostic, preventative, or therapeutic interventions for eye diseases or disorders. This NOFO is specifically intended for early-stage clinical trials with greater than minimal risk that include strong preliminary and/or pre-clinical data and have a well described Commercialization Plan.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html</a>	Up to \$2 million, for up to 3 years	Proposal: 1/30/24





# Recurring Opportunities

December 7, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)</b>		
66.	Open-Office Broad Agency Announcement (BAA)  75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems.  <a href="https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view">https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view</a>	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		<b>AIR FORCE (3)</b>		
67.	Airman Readiness Medical Research (ARMR) Hybrid BAA  FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332</a>	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
68.	Research Interests of the Air Force Office of Scientific Research  FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD).  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653">https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653</a>	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis



	Title and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE</b>		
69.	Research Interests of the United States Air Force Academy  USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175">https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175</a>	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		<b>ARMY (8)</b>		
70.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB  CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems.  <a href="https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view">https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
71.	USAMRDC Broad Agency Announcement for Extramural Medical Research  HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725">https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725</a>	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
72.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development  HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586">https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586</a>	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
73.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research  W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. <a href="#">Topics</a> include Biotronics, Genetics, and Neurophysiology of Cognition.  <a href="https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view">https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
74.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research  W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. <a href="https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view">https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
75.	Army Applications Lab BAA for Disruptive Applications  W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517">https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517</a>	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
76.	Army Research Office Broad Agency Announcement Staff Research Program  W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. <a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
77.	Army Combat Capabilities Development Command Broad Agency Announcement  W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		<b>BARDA (2)</b>		
78.	BARDA Broad Agency Announcement  BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). <a href="https://sam.gov/opp/645772ab7baf41d7aa0a6cbbec012147/view">https://sam.gov/opp/645772ab7baf41d7aa0a6cbbec012147/view</a>	Dependent upon proposal	Proposal: 9/25/28



	Title and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BARDA</b>		
79.	BARDA DRIVe EZ-BAA <a href="#">DRIVeEZBAA22100SOL00003</a>	Deadlines vary by AOI" "BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #19: Healing Lungs; AOI #20: DRIVE Forward; AOI #26: Agnostic Diagnostic. <a href="https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view">https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view</a>	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<b>DARPA (2)</b>		
80.	Biological Technologies BAA <a href="#">HR001123S0045</a>	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. <a href="https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view">https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view</a>	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
81.	Defense Sciences Office, Office-wide <a href="#">HR001123S0053</a>	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. <a href="https://sam.gov/opp/972be70efd7e4608b01311466edf6b0f/view">https://sam.gov/opp/972be70efd7e4608b01311466edf6b0f/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24
		<b>DEFENSE THREAT REDUCTION AGENCY (2)</b>		
82.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) <a href="#">HDTRA1-14-24-FRCWMD-BAA</a>	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. <a href="https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view">https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view</a>	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
83.	Research and Development Innovations Broad Agency Announcement <a href="#">HDTRA1-22-S-0003</a>	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at <a href="https://www.dtra.mil/">https://www.dtra.mil/</a> ): <ul style="list-style-type: none"> <li>• Understand current and emerging WMD situations, threats, and capabilities</li> <li>• Enable effective and integrated WMD deterrence</li> <li>• Control, disable, and defeat current and emerging WMD threats</li> <li>• Protect the force and mitigate crises from WMD</li> <li>• Enable cross-cutting capabilities</li> </ul> <a href="https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view">https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view</a>	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEPARTMENT OF ENERGY (1)</b>		
84.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program  DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=350408">https://www.grants.gov/web/grants/view-opportunity.html?oppld=350408</a>	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		<b>NATIONAL SCIENCE FOUNDATION (1)</b>		
85.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I)  NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. The NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required <a href="#">Project Pitch</a> allows startups and small businesses to get quick feedback. View the <a href="#">full list of topics</a> .  <a href="https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm">https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm</a>	Up to \$275,000 for up to 1 year	<a href="#">Project pitches</a> accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 1/9/24
		<b>NAVY (3)</b>		
86.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies  N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology.  <a href="https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view">https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
87.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology  N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations.  <a href="https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine">https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24
88.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research  N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2.  <a href="https://sam.gov/opp/ee708f6d2e244d0bb59d582c0362d9d1/view">https://sam.gov/opp/ee708f6d2e244d0bb59d582c0362d9d1/view</a>	Dependent upon proposal and award mechanism	White papers accepted through 12/29/23







### Terms

**AD/ADRD:** Alzheimer's Disease / Alzheimer's Disease Related Dementias

**Aoi:** Area of Interest

**BAA:** Broad Agency Announcement

**BBB:** Blood-Brain Barrier

**CNS:** Central Nervous System

**FOA:** Funding Opportunity Announcement

**IC:** NIH Institutes and Centers

**NOFO:** Notice of Funding Opportunity

**NOSI:** Notice of Special Interest

**PI:** Principal Investigator

**PTSD:** Post-Traumatic Stress Disorder

**RFI:** Request for Information

**RFP:** Request for Proposal

**SBIR:** Small Business Innovation Research

**SDOH:** Social Determinants of Health

**STTR:** Small Business Technology Transfer

**SUD:** Substance Use Disorder

**TRL:** Technology Readiness Level

**VCID:** Vascular Contributions to Cognitive Impairment and Dementia

### Agencies

**ARPA-H:** Advanced Research Projects Agency for Health

**ASPR:** Administration for Strategic Preparedness and Response

**BARDA:** Biomedical Advanced Research and Development Authority

**CDC:** Centers for Disease Control and Prevention

**CDMRP:** Congressionally Directed Medical Research Programs

**DARPA:** Defense Advanced Research Projects Agency

**DHA:** Defense Health Agency

**DoD:** Department of Defense

**FDA:** U.S. Food and Drug Administration

**MTEC:** Medical Technology Enterprise Consortium

**NIH:** National Institutes of Health

[Back to Table of Contents](#)

## GBG Acronyms

*Updated Monthly*

December 7, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

**NSF:** National Science Foundation

**PCORI:** Patient-Centered Outcomes Research Institute

**USAMRDC:** U.S. Army Medical Research and Development Command

**USAMRIID:** U.S. Army Medical Research Institute of Infectious Diseases

**USSOCOM:** United States Special Operations Command

### NIH Institutes and Centers

**CC:** NIH Clinical Center

**CIT:** NIH Center for Information Technology

**CSR:** NIH Center for Scientific Review

**FIC:** Fogarty International Center

**NCATS:** National Center for Advancing Translational Sciences

**NCCIH:** National Center for Complementary and Integrative Health

**NCI:** National Cancer Institute

**NEI:** National Eye Institute

**NHGRI:** National Human Genome Research Institute

**NHLBI:** National Heart, Lung, and Blood Institute

**NIA:** National Institute on Aging

**NIAAA:** National Institute on Alcohol Abuse and Alcoholism

**NIAID:** National Institute of Allergy and Infectious Diseases

**NIAMS:** National Institute of Arthritis & Musculoskeletal & Skin Diseases

**NIBIB:** National Institute of Biomedical Imaging and Bioengineering

**NICHD:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**NIDA:** National Institute on Drug Abuse

**NIDCD:** National Institute on Deafness and Other Communication Disorders

**NIDCR:** National Institute of Dental and Craniofacial Research

**NIDDK:** National Institute of Diabetes and Digestive and Kidney Diseases

**NIEHS:** National Institute of Environmental Health Sciences

**NIGMS:** National Institute of General Medical Sciences

**NIMH:** National Institute of Mental Health

**NIMHD:** National Institute on Minority Health and Health Disparities

**NINDS:** National Institute of Neurological Disorders and Stroke

**NINR:** National Institute of Nursing Research

**NLM:** National Library of Medicine

